Trial reportBlood2017
Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.
6 registry-linked trialsOpen access · bronzeAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 149 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed, 1 pooled it
8.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Wilms' Tumor (WT1) Antigen-targeted Dendritic Cell Vaccination to Prevent Relapse in Adult Patients With Acute Myeloid Leukemia: a Multicenter Randomized Phase II Trial
Adjuvant Dendritic-Cell Immunotherapy Plus Temozolomide Following Surgery and Chemoradiation in Patients With Newly Diagnosed Glioblastoma
First-line Immunotherapy Using Wilms' Tumor Protein 1 (WT1)-Targeted Dendritic Cell Vaccinations for Malignant Pleural Mesothelioma
NCT04911621 phase1 / phase2completednot on this mapstarted 2021, after this paper: background citation
Adjuvant Dendritic Cell Immunotherapy Complementing Conventional Therapy for Pediatric Patients With High-grade Glioma and Diffuse Intrinsic Pontine Glioma
Dendritic Cell Vaccination for the Adult Ovarian Cancer
NCT05765084 phase1 / phase2recruitingnot on this mapstarted 2023, after this paper: background citation
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
Who cites it
149 citing papers in PubMed, 1 synthesis or guideline pooled it, 230 citations in OpenAlex.
- Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics.Frontiers in oncology · 2020Pooled it
- Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia.Blood neoplasia · 2025Trial
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.Journal of hematology & oncology · 2025Trial
- First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience.Cancer immunology, immunotherapy : CII · 2022Trial
- A phase I/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients.Human vaccines & immunotherapeutics · 2021Trial
- Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.Cancer immunology, immunotherapy : CII · 2019Trial
- Exploring the potential of mRNA vaccines in combatting communicable and non-communicable diseases in low-income and lower-middle-income countries.Annals of medicine and surgery (2012) · 2026Review
- Advances inMolecular therapy. Nucleic acids · 2026Review
- Immunotherapy in acute myeloid leukemia: The antibodies, TriKEs, and CARs on the arduous road to cure.Blood reviews · 2026Review
- Dendritic cells in hematologic malignancies: a brief review of immunoregulation to new perspectives.Biochemia medica · 2026Review
- Increasing Transfection of Human Monocyte-Derived Dendritic Cells by Optimizing Lipid Nanoparticle Ionizable Lipid and mRNA Uridine Modification.Pharmaceutics · 2026Article
- Innovative combinatory approaches with dendritic cell-based vaccines: bridging preclinical insights and clinical challenges.Clinical and experimental medicine · 2026Review
- mRNA vaccines in cancer immunotherapy: current progress and perspectives in solid tumors and hematologic malignancies.MedScience · 2026Review
- RNA-Based Therapeutic Strategies in Multiple Myeloma: From Molecular Targets to Delivery and Clinical Translation.International journal of molecular sciences · 2026Review
- Molecularly targeted therapy and immunotherapy in leukemias.Journal of hematology & oncology · 2026Review
- Leukemic Transdifferentiation: From Pathological Plasticity to Dendritic Cell-Based Immunotherapy.Biomedicines · 2025Review
- mRNA therapeutics: Transforming medicine through innovation in design, delivery, and disease treatment.Molecular therapy. Nucleic acids · 2025Review
- mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics.Cancer innovation · 2025Review
- Monitoring of (Leukemia-Specific) Immune Cells in Stages, Treatment Groups and in the Course of Disease and Therapy Contributes to Qualify Antileukemic Potential and Survival in Patients with AML.International journal of molecular sciences · 2025Article
- The AML immune paradox: decoding escape pathways and pioneering checkpoint, vaccine, and combination strategies.Clinical and experimental medicine · 2025Review
89 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 5 institutions in 4 countries.
Sébastien AnguilleAntwerp University Hospital, Antwerp, Belgium.
Ann L Van de VeldeAntwerp University Hospital, Antwerp, Belgium.
Evelien L SmitsVaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Viggo F Van TendelooVaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Gunnar JuliussonDepartment of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Nathalie CoolsVaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Griet NijsAntwerp University Hospital, Antwerp, Belgium.
Barbara SteinAntwerp University Hospital, Antwerp, Belgium.
Eva LionVaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Ann Van DriesscheAntwerp University Hospital, Antwerp, Belgium.
Irma VandenboschAntwerp University Hospital, Antwerp, Belgium.
Anke VerlindenAntwerp University Hospital, Antwerp, Belgium.
Alain P GadisseurAntwerp University Hospital, Antwerp, Belgium.
Wilfried A SchroyensAntwerp University Hospital, Antwerp, Belgium.
Ludo MuylleAntwerp University Hospital, Antwerp, Belgium.
Katrien VermeulenAntwerp University Hospital, Antwerp, Belgium.
Marie-Berthe MaesAntwerp University Hospital, Antwerp, Belgium.
Kathleen DeiterenAntwerp University Hospital, Antwerp, Belgium.
Ronald MalfaitAntwerp University Hospital, Antwerp, Belgium.
Emma GostickDepartment of Infection, Immunity and Biochemistry, Cardiff University School of Medicine, Cardiff, United Kingdom; and.
Martin LammensAntwerp University Hospital, Antwerp, Belgium.
Marie M CouttenyeAntwerp University Hospital, Antwerp, Belgium.
Philippe JorensAntwerp University Hospital, Antwerp, Belgium.
Herman GoossensAntwerp University Hospital, Antwerp, Belgium.
David A PriceDepartment of Infection, Immunity and Biochemistry, Cardiff University School of Medicine, Cardiff, United Kingdom; and.
Kristin LadellDepartment of Infection, Immunity and Biochemistry, Cardiff University School of Medicine, Cardiff, United Kingdom; and.
Yoshihiro OkaDepartment of Respiratory Medicine, Allergy & Rheumatic Diseases.
Fumihiro FujikiDepartment of Cancer Immunology, and.
Yusuke OjiDepartment of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan.
Haruo SugiyamaDepartment of Cancer Immunology, and.
Zwi N BernemanAntwerp University Hospital, Antwerp, Belgium.
Antwerp University Hospital · BEUniversity of Antwerp · BECardiff University · GBOsaka University · JPSkåne University Hospital · SE
Funding
Wellcome Trust
Abstract
Relapse is a major problem in acute myeloid leukemia (AML) and adversely affects survival. In this phase 2 study, we investigated the effect of vaccination with dendritic cells (DCs) electroporated with Wilms' tumor 1 (
Indexed as
VaccinationAgedBiomarkers, TumorCancer VaccinesCytokinesDendritic CellsDisease-Free SurvivalElectroporationFemaleHumansKaplan-Meier EstimateLeukemia, Myeloid, AcuteMaleRecurrenceRemission InductionRNA, MessengerBiomarkers, TumorCancer VaccinesCytokinesRNA, MessengerWT1 Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT01686334ClinicalTrials.gov
NCT02649582ClinicalTrials.gov
NCT02649829ClinicalTrials.gov
NCT04911621ClinicalTrials.gov
NCT05270720ClinicalTrials.gov
NCT05765084ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.